SLS SELLAS Life Sciences Group, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1390478 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-37.8%
TTM EPS YoY28.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-40.3%
ROA-37.1%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets6.6%
Debt / equity0.00x
Current ratio14.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-8.8%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | $0 | $1.00M | $7.60M |
| Cost of revenue | $0 | $0 | $0 | $100,000 | $200,000 |
| Gross profit | — | — | $0 | $900,000 | $7.40M |
| R&D expense | $16.02M | $19.10M | $24.01M | $20.27M | $15.67M |
| SG&A expense | $12.25M | $12.42M | $13.86M | $12.58M | $11.32M |
| Operating income | -$28.27M | -$31.51M | -$37.87M | -$41.95M | -$25.29M |
| Pretax income | -$26.86M | -$30.88M | -$37.34M | -$41.30M | -$20.94M |
| Income tax | $0 | $0 | $0 | $0 | -$237,000 |
| Net income | -$26.86M | -$30.88M | -$37.34M | -$41.30M | -$20.70M |
| EPS (basic) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| EPS (diluted) | -0.25 | -0.50 | -1.34 | -2.13 | -1.34 |
| Weighted avg. shares (diluted) | 109.05M | 61.20M | 27.78M | 19.40M | 15.48M |
| Banking | |||||
| Net interest income | — | — | $525,000 | $317,000 | $6,000 |
| Balance sheet | |||||
| Cash & equivalents | $71.79M | $13.99M | $2.63M | $17.23M | $21.45M |
| Receivables | — | — | — | — | $0 |
| Current assets | $75.21M | $16.33M | $3.17M | $17.76M | $23.04M |
| Goodwill | $1.91M | $1.91M | $1.91M | $1.91M | $1.91M |
| Total assets | $78.34M | $19.43M | $6.22M | $20.94M | $26.27M |
| Current liabilities | $7.02M | $9.51M | $13.73M | $15.52M | $4.98M |
| Total liabilities | $7.47M | $9.97M | $14.20M | $16.09M | $5.93M |
| Shareholders' equity | $70.87M | $9.46M | -$7.98M | $4.85M | $20.35M |
| Shares outstanding | 153.10M | 73.98M | 32.13M | 21.01M | 15.90M |
| Cash flow statement | |||||
| Operating cash flow | -$28.39M | -$35.40M | -$31.41M | -$23.81M | -$26.02M |
| Investing cash flow | — | $0 | -$5.50M | -$4.50M | $0 |
| Financing cash flow | $86.30M | $46.76M | $22.32M | $24.08M | $12.07M |
| Stock-based compensation | $1.96M | $1.56M | $2.09M | $1.73M | $1.01M |
Free plan shows the latest 5 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.